

Luce Mosselmans et al.

Effect of donor exclusion on blood safety

This online first version has been peer-reviewed, accepted and edited,
but not formatted and finalized with corrections from authors and proofreaders

Effect of donor exclusion criteria on blood safety and volume of donations: a systematic review of modelling studies

Luce Mosselmans,^a Mart P Janssen,^b Hendrik B Feys,^c Emmy de Buck,^a Fritz Schiltz,^c Peter Vandenberghe,^d Philippe Vandekerckhove^c & Hans Van Remoortel^a

^a Centre for Evidence-Based Practice, Belgian Red Cross-Flanders, Motstraat 42, 2800 Mechelen, Belgium.

^b Transfusion Technology Assessment Department, Sanquin Research, Amsterdam, Kingdom of the Netherlands.

^c Belgian Red Cross-Flanders, Blood Services, Mechelen, Belgium.

^d Department of Haematology, University Hospitals Leuven, Leuven, Belgium.

Correspondence to Luce Mosselmans (email: Luce.mosselmans@rodekruis.be).

(Submitted: 19 June 2025 – Revised version received: 7 October 2025 – Accepted: 6 November September 2025 – Published online: 22 January 2026)

Abstract

Objective To assess the effect of easing bans and deferral policies on blood donation from men who have sex with men on blood safety and volume from modelling studies.

Methods We searched four databases (PubMed®, Embase®, CINAHL and Web of Science) for modelling studies on the impact of replacing bans or deferrals on blood donations from men who have sex with men with shorter deferral periods or no deferrals. We synthesized and compared findings from the different modelling studies, and assessed risk of bias and certainty of evidence.

Findings Fourteen publications were included in the study. All the studies estimated the human immunodeficiency virus (HIV) residual risk of an HIV infected blood donation being received, going undetected through screening and entering the blood supply. Despite medium to large increases in risks in relaxing donor policies for men who have sex with men, the absolute HIV residual risk remained very low in all scenarios, ranging between 0.05 and 1.1 HIV positive units per million donations. The increase in donors ranged from 0.04% to 2.10%. No models covered other transfusion-transmissible infections such as syphilis or hepatitis C.

Conclusion Modelled HIV residual risk estimates increased slightly with relaxed policies on donations from men who have sex with men. However, differences in risk and blood volume estimates between different policies are generally very small. To support decisions on easing donor policies for men who have sex with men, models should also quantify residual risks for non-HIV transfusion-transmissible infections, such as syphilis.

Introduction

The deferral, that is, the temporary or permanent exclusion, of blood donors at higher risk of having transfusion-transmissible infections, such as men who have sex with men, commercial sex workers or injection drug users, is a strategy to increase the safety of blood products.^{1,2} This strategy, along with pathogen screening, was introduced as a response to transfusion-transmitted human immunodeficiency virus (HIV) infection in the initial years of the acquired immunodeficiency disease syndrome (AIDS) epidemic. However, delays in adopting adequate risk reduction strategies in the 1970s to 1990s, even after the causative agent of AIDS was identified, resulted in thousands of preventable infections and related disease worldwide³. Subsequent legal inquiries in several countries, including France, Japan and United Kingdom of Great Britain and Northern Ireland, criticized policy-makers and blood service authorities for their inaction and failures in preserving blood safety.^{3,4} These historical failures underscored the need for precautionary, evidence-based approaches to donor selection and testing, and they shape the ethical and operational frameworks governing blood safety today.⁵ Deferrals for men who have sex with men are increasingly seen as stigmatizing, especially in high-income countries with relatively low HIV prevalence and current sensitive screening tests.^{6,7} Nonetheless, in Europe, the incidence of HIV is disproportionately high in some subpopulations including men who have sex with men. According to the European Centre for Diseases Control and Prevention, nearly half of cases of HIV infection in western Europe in 2022 were men who have sex with men.⁸

In the past decade, blood establishments in several countries (Australia, Canada, France, Germany, Kingdom of the Netherlands, United Kingdom and United States of America) have modified blood donor criteria by shortening the length of deferral for men who have sex with men or by replacing exclusion with a risk assessment for all blood donors, regardless of sex or sexual orientation (also referred to as individual risk assessment).^{9,10} In 2022, we conducted a systematic review of the risk of transfusion-transmitted infections in blood donors and deferral policies for men who have sex with men and concluded that observational studies yielded limited evidence of the impact of 3-month deferral for men who have sex with men or risk-based deferrals on the risk of transfusion-transmissible infections.¹¹ However, our review did not include evidence from modelling studies. Modelling studies may offer additional information to support decision-making on donor deferral policies.

In this article, we therefore aim to identify, critically appraise and synthesize modelling studies that estimated the impact of easing deferral policies for men who have sex with men on the residual risk of transfusion-transmissible infections and/or the number of donations. This review is intended to support blood establishments in (re)evaluating deferral policies for men who have sex with men through modelled data from different countries and summarizing the methods available to assess the risk of transfusion-transmissible infections within their specific settings. We do not aim to make any policy recommendations, as each jurisdiction should interpret the risks within their local context.

Methods

This systematic review was registered in PROSPERO (CRD42024524737) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines¹² (online repository).¹³

Eligibility criteria

Studies addressing the following PICOD question were included, “In donors (population), does easing the deferral policy for donors who are men who have sex with men (intervention versus comparator) have an impact on the blood safety or volume (outcomes) in modelling studies (design)?” We reviewed studies based on predefined criteria (online repository).¹³

Data sources and searches

We searched four databases on 27 April 2025: PubMed®, Embase®, CINAHL and Web of Science. We developed search strings according to the eligibility criteria and adapted to each database (Box 1; available from: <https://www.who.int/publications/journals/bulletin>).

Study selection

We screened articles based on title, abstract and full text according to the eligibility criteria. We screened the reference lists of the included peer-reviewed journal articles and the first 20 similar articles displayed in PubMed® for additional relevant records.

Data extraction and synthesis

We extracted the following data: type of model; setting; the modelled intervention (transfusion-transmissible infection(s) assessed and deferral policy for men who have sex with men at baseline and modelled); modelled outcomes (blood safety and number of donations); and the modelling assumptions made.

We synthesized and compared findings from the different modelling studies and used a narrative synthesis approach to assess the results based on length of deferral. No meta-analysis was conducted.

Risk of bias and grading

We assessed the risk of bias using a grading scale¹⁴ that was developed based on the modelling good practices checklists^{15,16} The grading scale has 14 questions on definitions, model methods, model inputs, fitting and validation, results, and conflicts of interest. Each question was scored 0, 1 or 2 points, resulting in an overall score ranging from 0 to 28. We categorized risk of bias as follows: ≤ 14 as high risk of bias; 15–18 as medium risk of bias; and ≥ 19 as low risk of bias. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to assess the overall certainty of the modelled evidence for each outcome and sorted by baseline versus modelled policy on men who have sex with men.¹⁷ We initially graded outcomes from modelling studies as high certainty evidence and then downgraded as required based on risk of bias, indirectness, imprecision, inconsistency and risk of publication bias.

Two authors undertook the study selection, data extraction and risk of bias assessment independently and they resolved discrepancies by discussion. Where necessary, they consulted a third reviewer.

Results

Study selection and features

We identified 2950 records through our search. After removing duplicates and screening titles and abstracts, we assessed 33 full-text articles, of which 14 met the inclusion criteria (Fig. 1 and online repository).¹³ Table 1 shows the characteristics of the 14 included studies. One study modelled the complete removal of risk-based deferrals, including for men who have sex with men, injection drug users and commercial sex workers.²⁶ Five models were deterministic mathematical equation models (i.e. parameters are fixed)^{19,21–23,25} while the other nine used stochastic models (i.e. parameters are described by probability distributions) where the final outcome was determined by Monte Carlo simulations.^{18,20,24,26–31} All 14 studies modelled the risk of HIV transmission; one study also included the risk of hepatitis B virus (HBV) transmission.²⁰ We did not find any studies investigating the risk of hepatitis C virus (HCV) or syphilis transmission. One study assessed the risk of infections in plasma donations,³⁰ while the other studies estimated risks in blood donations.

The models included a combination of the following sources of risk: (i) risk of undetected prevalent infections due to assays false-negative error rates (11 models);^{18–21,23–25,27,28,30,31} (ii) risk of recent infections in the silent window period (10 models);^{19,21–23,25,26,28–31} and (iii) risk of human error in laboratory processes (seven models).^{18,19,23,24,27,28,30} To estimate these risks, all the models applied several assumptions on the rate of men who have sex with men in the general population, the prevalence and incidence of transfusion-transmissible infections in donors who are men who have sex with men, the false-negative rates of laboratory tests, the length of window periods and the process error rates, based on the best available data in their context. For detailed information about the assumptions and key input variables of each model, see online repository.¹³

All the studies estimated the HIV residual risk which is the risk of an HIV infected blood donation being received, going undetected through screening and entering the blood supply. This risk is therefore a combination of the prevalence and incidence of HIV in the donor population, the (self) deferral of donors, the sensitivity of testing assays and rates of human errors or quarantine release errors.

Risk of bias of studies

Table 2 shows the results of the risk of bias assessment for each included model (online repository).¹³ The overall risk of bias varied and models ranged from very low to high risk of bias. The main limitation identified was the lack of validation of models, with only two studies of validated models.^{27,31} In general, the studies clearly defined their objectives, the setting and population of interest, the baseline and modelled deferral policies for men who have sex with men, and the outcomes. Three models used modelling methods which were either inappropriate or poorly described and were therefore not reproducible.^{19,22,30} Several models did not use appropriate data sources or did not justify all underlying assumptions.^{18,19,22,26,30} We identified limitations in the reporting, interpretation and discussion of results, and/or their uncertainty, in nine models.^{18,19,21–24,26,30,31} Two studies did not report a sensitivity analysis.^{18,24}

Synthesis of findings

Detailed tables of findings, including the overall certainty of modelled evidence (for each outcome) are in the online repository.¹³ Nine studies modelled the HIV residual risk per million donations as outcome of the model.^{18,19,21–23,27–29,31}

Table 3 gives an overview of the modelled estimates of outcomes per intervention. Absolute increases in HIV residual risk were observed in all plausible scenarios, ranging from 0.004% to 300%. In absolute numbers, this translated to increases ranging from 0.001 to 0.120 additional HIV-positive blood units per million donations. For the World Health Organization European Region, estimating that 17 million donations are made yearly, this figure would translate to between 0 and 2 additional infected blood products per year.³² The modelled residual risk under relaxed policies on donations from men who have sex with men remained low in all plausible scenarios assessed, ranging from 0.05 to 1.10 per million donations (Fig. 2).

Additionally, moderate certainty of the modelled evidence indicated that increases in donors from easing deferrals for men who have sex with men were relatively small (between 0.04% and 2.10% increase in total donations) for all comparisons.

Sensitivity analysis

While only a few models conducted sensitivity analyses, 12 papers assessed uncertainty by modelling several scenarios, assuming different hypotheses about different parameters of the model. The following parameters affected the estimated outcomes: the prevalence and incidence of HIV among the blood donor population and men who have sex with men population;^{20–23,27–31} rates of donor non-compliance with deferral rules (that is, not reporting risk behaviour at donor screening);^{19,20,23} and the length of the window period.^{21,27} Testing error rates did not significantly influence the outcome estimations.^{27,30} Details of individual papers are in the online repository).¹³

Discussion

We identified 14 papers with models estimating the HIV residual risk, and one also estimating the HBV risk, in different scenarios of eased deferral policies on blood donation by men who have sex with men. Twelve of the papers also reported the effect on the number of blood donors or donations.

The modelled HIV residual risk increased slightly with eased policies for men who have sex with men; however, differences were often (very) small and the estimated residual risk remained very low (between 0.05 and 1.10 per million donations) in all plausible scenarios. The estimated increase in blood donors or donations was also small. More inclusive policies on blood donation by men who have sex with men are therefore unlikely to have a very large effect on total blood volume available for transfusion. The interpretation of the

relative increase in risk and the absolute risk may be dependent on the perspective taken. From the perspective of a blood bank that must take a cautious approach, an increase in HIV risk by 300% (the highest effect found in this review) will be intolerably high. However, this 300% increase in risk translates to an absolute increase of 0.04 additional HIV-positive blood units per million donations, which may be interpreted as a tolerable increase in risk from a societal perspective, as it is comparable to baseline risk.

The main strength of our study is the use of high-quality methods to provide the best available and most up-to-date body of modelled evidence. A limitation is that, in the absence of consensus tools on methods for the systematic reviews of modelling studies, the risk of bias was assessed using a checklist derived from the literature on modelling best practices. In this list, some of the items assessed reporting rather than quality and may not be suited for assessing risk of bias.^{14,16,17}

We also identified two important limitations concerning the modelled evidence. First, the models in our review only assessed the risk of HIV transmission, and only one estimated the residual risk of HBV infection. However, HCV, syphilis and emerging diseases should also be considered when assessing blood safety. Men who have sex with men are a risk group for sexually transmitted infections, with a higher prevalence of HIV, hepatitis B and syphilis. They are also potentially at higher risk of emerging diseases that are sexually transmitted, as was seen during the first global outbreak of mpox in 2022.^{33,34} Risk-based deferral of donors is an important preventive measure for emerging diseases and for so-called escape variants of existing infectious diseases, for which no screening tests are performed or are available. Therefore, donor selection acts as the main barrier against transfusion-transmissible infections.

The second limitation relates to the uncertainty of the modelled outcomes, resulting from several underlying assumptions. Models estimate the risk of HIV transmission in the blood supply based on assumptions such as the prevalence and incidence of HIV in men who have sex with men, the rates of donor non-compliance, and/or the length of the window period for testing. Assumptions about donor compliance might be imprecise, as it is unclear whether shortening deferral periods has an impact on donor compliance.^{35–37} It is uncertain whether deferral rules that are not seen as unduly discriminating will be better accepted and respected and whether non-compliant donors donating under deferral rules would continue to donate after the policy change, thereby reducing overall non-compliance. As donor non-compliance was shown to affect the estimated risks in the sensitivity analyses of the models

included in this review, the uncertainty around rates of donor non-compliance might affect the modelled estimates of risk.

The use of pre-exposure prophylaxis to reduce HIV transmission might pose a risk to blood safety. Although extremely rare, breakthrough infections might go undetected due to the medication suppressing viral loads below the detection limits of screening assays.³⁸ In parallel, treatment-as-prevention strategies and newer long-acting pre-exposure prophylaxis formulations are further transforming HIV epidemiology and prevention.³⁹ The increasing availability of pre-exposure prophylaxis for high-risk groups has the potential to significantly reduce the prevalence and incidence of HIV, but may increase the prevalence of other sexually transmitted infections in men who have sex with men.⁴⁰ The prevalence of infections in the donor population is a key parameter to modelling the blood safety of evolving deferrals for men who have sex with men. Thus, future models should aim to include the effects of pre-exposure prophylaxis in their underlying assumptions.

Decisions on blood donor deferral policies for men who have sex with men should be informed by both estimates from modelling studies, which investigate potential policy changes, and by observational studies, which evaluate the impact of current or past policies using real-world data. Future research on this topic should integrate both forms of evidence to provide a comprehensive understanding of blood safety risks. With the availability of high-quality, validated models, we urge blood institutions considering policy updates to assess the associated risks in their specific contexts through modelling. At the same time, they should draw on insights from observational studies, both for HIV and other transfusion-transmissible infections. All the models we identified estimated blood safety in Canada, USA and high-income European countries, which have a specific epidemiological context, such as low HIV prevalence, and use sensitive nucleic acid tests for screening. Therefore, our results cannot be extrapolated to other contexts with different blood donor demographics, and different prevalence and incidence rates of HIV or other transfusion-transmissible infections. As the risk of HIV in blood transfusion is related to blood donors being unknowingly HIV positive, the residual risk might be higher in countries that are struggling to reach one of the HIV elimination targets of 90% of people living with HIV being diagnosed.

As some of the models in our review were conducted several years ago and were followed by a policy change, the outcomes of the modelling can be compared with observed data. In 2016, the estimates of the six modelling studies conducted between 2003 and 2013 were compared with the observed HIV prevalence in donors after the introduction of 5-year

and 1-year deferrals for men who have sex with men in Australia, Canada and the United Kingdom.⁴¹ All six models predicted an increase in HIV-positive male donors that was higher than actually observed.⁴¹ This finding may indicate the limited predictive power of modelling studies. The assumptions taken by the models about future conditions may be incorrect. The decrease in HIV incidence in men who have sex with men due to the recent availability of pre-exposure prophylaxis in high-income countries was not accounted for in the models, which may explain overestimations of risks in recent models. Our previous systematic review concluded that the certainty of evidence from observational studies was very low, in part due to limitations in study design and very low base rates.¹¹ The conclusions about the absence of an increased HIV prevalence in observational studies should therefore also be interpreted with caution.¹¹ Recent data from countries that shifted to individual risk assessment show higher syphilis rates among donors who are men who have sex with men.^{42,43} Our review found no models estimating syphilis risk. Continuous surveillance of trends in transfusion-transmissible infections after policy changes, as well as models including HBV, HCV and syphilis, are needed to inform future policy.

Modelling studies can incorporate the prevalence of infections in donors and the effects of subsequent protective measures, such as laboratory screenings and pathogen reduction technology for plasma and platelets, to estimate the residual risk of transmission (that is, the probability that an infected blood product would be undetected in screening assays and/or released for transfusion to a patient). However, the interpretation for clinical relevance of the residual risk is not straightforward as the administration of an infected blood product may not always lead to infection and/or disease in a patient.

In our review, only one study assessed the safety of plasma and modelled the effects of pathogen reduction technology.³⁰ A recent modelling study found that pathogen reduction technology for whole blood could reduce the reliance on blood donor selection for blood safety.⁴⁴ Since false negative errors with nucleic acid tests are rare, the main risk of infections in blood supply are infections in the window period, where the viral load is lower than the detection limits of assays. Pathogen reduction technology could further reduce this viral load to the point that blood products would be minimally infectious. Based on the model, the authors speculated that the combination of nucleic acid tests and pathogen reduction technology complemented each other to reduce risk of infections and that donor deferrals could be relaxed.⁴⁴ While blood banking strives for harm reduction wherever possible, the financial sustainability of interventions should always be considered.^{45,46} The cost-

effectiveness of donor selection, laboratory screening and pathogen reduction technology should be analysed to inform decision-making for appropriate allocation of funds for optimized blood safety.⁴⁵

To conclude, modelling evidence from high-income countries indicates that the residual risk for HIV transmissions by blood transfusion would increase slightly if deferral policies were eased for donations from men who have sex with men. However, the absolute residual risk of HIV transmission remains very small (between 0.05 and 1.10 per million blood donations). Additionally, the impact of easing donor deferral policies on the number of additional donations is small. Decision-making on donor policy changes for men who have sex with men requires models that estimate residual risks for transfusion-transmissible infection beyond HIV.

Funding:

This work was funded by the Foundation for Scientific Research of the Belgian Red Cross. Belgian Red Cross-Flanders is responsible for supplying adequate quantities of safe blood products to hospitals in Flanders and Brussels on a continuous basis and is financially compensated for this activity.

Competing interests:

LM, HBF, EDB, FS, PhV, HVR are employed by the Belgian Red Cross-Flanders. MPJ is employed by the Sanquin Blood Supply Foundation, responsible for safe blood supply in the Kingdom of the Netherlands. The authors disclose no conflicts of interest.

References

1. Bloch EM. Transfusion-transmitted infections. *Ann Blood*. 2022;7:20. <https://doi.org/10.21037/aob-21-60>
2. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. *Blood*. 2019 Apr 25;133(17):1854–64. <https://doi.org/10.1182/blood-2018-11-833996> PMID:30808637
3. Europe's HIV-contaminated blood. *Nature*. 1993 Nov 11;366(6451):95. <https://doi.org/10.1038/366095a0> PMID:8232561
4. Ablin RJ. Japanese HIV-blood trial. *Lancet*. 2002 Feb 2;359(9304):446. [https://doi.org/10.1016/S0140-6736\(02\)07581-5](https://doi.org/10.1016/S0140-6736(02)07581-5) PMID:11844550
5. Blood donor selection: guidelines on assessing donor suitability for blood donation. Geneva: World Health Organization; 2012. Available from: <https://iris.who.int/handle/10665/76724> [cited 2025 Dec 5].
6. Wilson K, Atkinson K, Keelan J. Three decades of MSM donor deferral policies. What have we learned? *Int J Infect Dis*. 2014 Jan;18:1–3. <https://doi.org/10.1016/j.ijid.2013.09.016> PMID:24211477
7. Pierik R, Verweij M, van de Laar T, Zaaijer H. Facing difficult but unavoidable choices: Donor blood safety and the deferral of men who have sex with men.

Bioethics. 2022 Oct;36(8):840–8. <https://doi.org/10.1111/bioe.13063>
PMID:35656585

8. HIV/AIDS surveillance in Europe 2023 (2022 data). Stockholm and Copenhagen: European Centre for Disease Prevention and Control and World Health Organization Regional Office for Europe; 2023. Available from: <https://iris.who.int/handle/10665/374425> [cited 2025 Dec 5].
9. Lee S. Towards de-deferral of MSM blood donors [abstract]. Vox Sang. 2022;117 Suppl 1:8.
10. Goldman M. MSM and blood donation: shifting to individualized risk assessment. Hematology (Am Soc Hematol Educ Program). 2023 Dec 8;2023(1):294–8. <https://doi.org/10.1182/hematology.2023000482> PMID:38066878
11. Schroyens N, Borra V, Compernolle V, Vandekerckhove P, De Buck E. Men who have sex with men and risk for transfusion-transmissible infections in blood donors in Western countries: A systematic review update. Vox Sang. 2023 Sep;118(9):709–20. <https://doi.org/10.1111/vox.13482> PMID:37322809
12. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021 Mar 29;372(160):n160. <https://doi.org/10.1136/bmj.n160> PMID:33781993
13. Mosselmans L, Janssen MP, Feys HB, de Buck E, Schiltz F, Vandenberghe P, et al. Effect of donor exclusion criteria on blood safety and volume of donations: a systematic review of modelling studies – supplementary material [online repository]. Charlottesville: Center for Open Science; 2025. <https://doi.org/10.17605/OSF.IO/RT2XB>
14. Harris RC, Sumner T, Knight GM, White RG. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Hum Vaccin Immunother. 2016 Nov;12(11):2813–32. <https://doi.org/10.1080/21645515.2016.1205769> PMID:27448625
15. Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012 Sep-Oct;32(5):667–77. <https://doi.org/10.1177/0272989X12454577> PMID:22990082
16. Fone D, Hollinghurst S, Temple M, Round A, Lester N, Weightman A, et al. Systematic review of the use and value of computer simulation modelling in population health and health care delivery. J Public Health Med. 2003 Dec;25(4):325–35. <https://doi.org/10.1093/pubmed/fdg075> PMID:14747592
17. Brozek JL, Canelo-Aybar C, Akl EA, Bowen JM, Bucher J, Chiu WA, et al.; GRADE Working Group. GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence-An overview in the context of health decision-making. J Clin Epidemiol. 2021 Jan;129:138–50. <https://doi.org/10.1016/j.jclinepi.2020.09.018> PMID:32980429
18. Germain M, Remis RS, Delage G. The risks and benefits of accepting men who have had sex with men as blood donors. Transfusion. 2003 Jan;43(1):25–33. <https://doi.org/10.1046/j.1537-2995.2003.00281.x> PMID:12519427

19. Soldan K, Sinka K. Evaluation of the de-selection of men who have had sex with men from blood donation in England. *Vox Sang.* 2003 May;84(4):265–73. <https://doi.org/10.1046/j.1423-0410.2003.00295.x> PMID:12757500
20. Anderson SA, Yang H, Gallagher LM, O'Callaghan S, Forshee RA, Busch MP, et al. Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. *Transfusion.* 2009 Jun;49(6):1102–14. <https://doi.org/10.1111/j.1537-2995.2009.02124.x> PMID:19320868
21. Davison KL, Brant LJ, Presanis AM, Soldan K. A re-evaluation of the risk of transfusion-transmitted HIV prevented by the exclusion of men who have sex with men from blood donation in England and Wales, 2005–2007. *Vox Sang.* 2011 Nov;101(4):291–302. <https://doi.org/10.1111/j.1423-0410.2011.01491.x> PMID:21535438
22. Pillonel J, Heraud-Bousquet V, Pelletier B, Semaille C, Velter A, Saura C, et al.; Blood Donor Epidemiological Surveillance Study Group. Deferral from donating blood of men who have sex with men: impact on the risk of HIV transmission by transfusion in France. *Vox Sang.* 2012 Jan;102(1):13–21. <https://doi.org/10.1111/j.1423-0410.2011.01509.x> PMID:21692806
23. Davison KL, Conti S, Brailsford SR. The risk of transfusion-transmitted HIV from blood donations of men who have sex with men, 12 months after last sex with a man: 2005–2007 estimates from England and Wales. *Vox Sang.* 2013 Jul;105(1):85–8. <https://doi.org/10.1111/vox.12024> PMID:23398193
24. Germain M, Robillard P, Delage G, Goldman M. Allowing blood donation from men who had sex with men more than 5 years ago: a model to evaluate the impact on transfusion safety in Canada. *Vox Sang.* 2014 May;106(4):372–5. <https://doi.org/10.1111/vox.12109> PMID:24877223
25. Ginsberg GM, Shinar E, Kopel E, Chemtob D. Should Men who have sex with Men be allowed to donate blood in Israel? *Isr J Health Policy Res.* 2016 Dec 13;5(1):60. <https://doi.org/10.1186/s13584-016-0123-2> PMID:27999657
26. Yang H, Anderson SA, Forshee R, Williams A, Epstein JS, Marks PW. Modeling complete removal of risk assessment questions in the USA predicts the risk of HIV exposure in blood recipients could increase despite the use of nucleic acid testing. *Vox Sang.* 2016 May;110(4):324–8. <https://doi.org/10.1111/vox.12375> PMID:26765975
27. Davison KL, Gregoire Y, Germain M, Custer B, O'Brien SF, Steele WR, et al.; the Surveillance, Risk Assessment, Policy Sub-Group of the ISBT Transfusion Transmitted Diseases Working Party. Changing the deferral for men who have sex with men - an improved model to estimate HIV residual risk. *Vox Sang.* 2019 Oct;114(7):666–74. <https://doi.org/10.1111/vox.12826> PMID:31373016
28. O'Brien SF, Grégoire Y, Pillonel J, Steele WR, Custer B, Davison KL, et al.; Surveillance, Risk Assessment and Policy Sub-group of the ISBT Transfusion Transmitted Diseases Working Party. HIV residual risk in Canada under a three-month deferral for men who have sex with men. *Vox Sang.* 2020 Feb;115(2):133–9. <https://doi.org/10.1111/vox.12867> PMID:31777098
29. Pillonel J, Pelat C, Tiberghien P, Sauvage C, Danic B, Martinaud C, et al. The evolving blood donor deferral policy for men who have sex with men: impact

on the risk of HIV transmission by transfusion in France. *Transfusion*. 2020 Mar;60(3):525–34. <https://doi.org/10.1111/trf.15677> PMID:32027031

30. Aubé E, Lewin A, O'Brien SF, Grégoire Y, Pillonel J, Steele WR, et al.; Surveillance, Risk Assessment and Policy Subgroup of the ISBT Transfusion Transmitted Infectious Diseases Working Party. HIV residual risk in Canada for apheresis source plasma donation without deferral for men who have sex with men. *Vox Sang*. 2022 Feb;117(2):201–7. <https://doi.org/10.1111/vox.13176> PMID:34268781

31. Caffrey N, Goldman M, Lewin A, Grégoire Y, Yi QL, O'Brien SF. Removing the men who have sex with men blood donation deferral: Informing risk models using Canadian public health surveillance data. *Transfus Clin Biol*. 2022 Aug;29(3):198–204. <https://doi.org/10.1016/j.trcli.2022.06.001> PMID:35987531

32. EBA [internet]. Brussels: European Blood Alliance; 2025. Available from: <https://europeanbloodalliance.eu/> [cited: 25 Dec 6].

33. Laurenson-Schafer H, Sklenovská N, Hoxha A, Kerr SM, Ndumbi P, Fitzner J, et al.; WHO mpox Surveillance and Analytics team. Description of the first global outbreak of mpox: an analysis of global surveillance data. *Lancet Glob Health*. 2023 Jul;11(7):e1012–23. [https://doi.org/10.1016/S2214-109X\(23\)00198-5](https://doi.org/10.1016/S2214-109X(23)00198-5) PMID:37349031

34. Bivegete S, McNaughton AL, Trickey A, Thornton Z, Scanlan B, Lim AG, et al. Estimates of hepatitis B virus prevalence among general population and key risk groups in EU/EEA/UK countries: a systematic review. *Euro Surveill*. 2023 Jul;28(30):2200738. <https://doi.org/10.2807/1560-7917.ES.2023.28.30.2200738> PMID:37498533

35. Caffrey N, Goldman M, Osmond L, Yi QL, Fan W, O'Brien SF. HIV incidence and compliance with deferral criteria over three progressively shorter time deferrals for men who have sex with men in Canada. *Transfusion*. 2022 Jan;62(1):125–34. <https://doi.org/10.1111/trf.16753> PMID:34854092

36. Johns CN, Simonson G, Hiwatig BM, Ross MW. Actions and attitudes of men who have sex with men under past, current, and hypothetical future blood donation deferral policies. *Transfus Med Rev*. 2022 Jul;36(3):152–8. <https://doi.org/10.1016/j.tmrv.2022.06.007> PMID:35927145

37. Lewin A, Grégoire Y, Delage G, Thibeault C, Viau C, Milot C, et al. Reported non-compliance with pre-donation screening among blood donors in Québec, Canada: A focus on the 3-month deferral for men who have sex with men. *Vox Sang*. 2022 Jul;117(7):966–70. <https://doi.org/10.1111/vox.13277> PMID:35377497

38. Leblanc JF, Custer B, Van de Laar T, Drews SJ, Germain M, Lewin A. HIV pre-exposure prophylaxis, blood donor deferral, occult infection, and risk of HIV transmission by transfusion: a fine balance between evidence-based donor selection criteria and transfusion safety. *Transfus Med Rev*. 2023 Jul;37(3):150754. <https://doi.org/10.1016/j.tmrv.2023.150754> PMID:37741792

39. Landovitz RJ, Scott H, Deeks SG. Prevention, treatment and cure of HIV infection. *Nat Rev Microbiol*. 2023 Oct;21(10):657–70. <https://doi.org/10.1038/s41579-023-00914-1> PMID:37344551

40. Georgiadis N, Papamichail D, Lytras T, Halkitis PN, Tzanakaki G, Kornarou E, et al. The impact of HIV preexposure prophylaxis on bacterial sexually transmitted infection occurrence in MSM: a systematic review and meta-analysis. *AIDS*. 2024 Jun 1;38(7):1033–45.
<https://doi.org/10.1097/QAD.0000000000003837> PMID:38669203
41. Germain M. The risk of allowing blood donation from men having sex with men after a temporary deferral: predictions versus reality. *Transfusion*. 2016 Jun;56(6 Pt 2):1603–7. <https://doi.org/10.1111/trf.13541> PMID:26948287
42. Tiberghien P, Lecam S, Huet J, Malard L, Tavenard T, Pillonel J, et al. Evolving deferral criteria for blood donation in France: Plasma donation by men who have sex with men. *Vox Sang*. 2023 Jun;118(6):440–6.
<https://doi.org/10.1111/vox.13435> PMID:37183555
43. Groves J, Apostoli A, Dodd RY, Stramer SL. Reinstatement and infectious disease rates among blood donors previously deferred under men who have sex with men time-based deferral. *Transfusion*. 2025 Aug;65(8):1472–83.
<https://doi.org/10.1111/trf.18299> PMID:40497820
44. Domingue MP, O'Brien SF, Grégoire Y, Lanteri MC, Stramer SL, Camirand Lemyre F, et al. Implementing pathogen reduction technology while discontinuing blood donor deferral criteria for sexual risk behaviors: A simulation study. *Transfusion*. 2024 Oct;64(10):1949–58.
<https://doi.org/10.1111/trf.17981> PMID:39126400
45. Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. *Transfus Med Rev*. 2009 Jan;23(1):1–12. <https://doi.org/10.1016/j.tmrv.2008.09.001> PMID:19056030
46. Jayawardena T, Hoad V, Styles C, Seed C, Bentley P, Clifford V, et al. Modelling the risk of transfusion-transmitted syphilis: a reconsideration of blood donation testing strategies. *Vox Sang*. 2019 Feb;114(2):107–16.
<https://doi.org/10.1111/vox.12741> PMID:30565234

Box 1. Search strategy, by database for studies on the effect of donor exclusion criteria on blood safety and volume of donations

PubMed®

("blood donors"[Mesh] OR "blood donor"[TIAB] OR "blood donors"[TIAB] OR "blood donation"[Mesh] OR "blood donation"[TIAB] OR "blood donations"[TIAB] OR "blood banks"[Mesh] OR "blood banks"[TIAB] OR "blood bank"[TIAB] OR "blood service"[TIAB] OR "blood services"[TIAB] OR "blood center"[TIAB] OR "blood centers"[TIAB] OR "blood centre"[TIAB] OR "blood centres"[TIAB] OR "blood transfusion"[Mesh] OR "transfusion"[TIAB])

AND

("hiv infections"[Mesh] OR "HIV"[TIAB] OR "hepatitis b virus"[Mesh] OR "hepatitis b"[TIAB] OR "HBV"[TIAB] OR "hepatitis c"[TIAB] OR "HCV"[TIAB] OR "treponemal infections"[Mesh] OR "syphilis"[TIAB] OR "treponema pallidum"[TIAB] OR "emerging"[TIAB] OR "residual risk"[TIAB] OR "infection"[TIAB] OR "infections"[TIAB] OR "transfusion-transmitted"[TIAB] OR "transfusion transmissible"[TIAB] OR "TTI"[TIAB] OR "blood safety"[Mesh] OR "blood safety"[TIAB] OR "transfusion safety"[TIAB])

AND

("models, theoretical"[Mesh] OR "models,statistical"[Mesh] OR "bayes theorem"[Mesh] OR "model"[TIAB] OR "models"[TIAB] OR "modelling"[TIAB] OR "modelling"[TIAB] OR "modelled"[TIAB] OR "modelled"[TIAB] OR "computer simulation"[Mesh] OR "simulation"[TIAB] OR "predict"[TIAB] OR "prediction"[TIAB] OR "predicted"[TIAB] OR "estimate"[TIAB] OR "estimates"[TIAB] OR "estimated"[TIAB] OR "estimation"[TIAB] OR "scenario"[TIAB] OR "scenarios"[TIAB])

AND

("deferral"[TIAB] OR "ban"[TIAB] OR "lifetime"[TIAB] OR "risk assessment"[TIAB] OR "men who have sex with men"[TIAB] OR "MSM"[TIAB] OR "men who have had sex with men"[TIAB] OR "homosexuality, male"[Mesh] OR "gay"[TIAB] OR "bisexual"[TIAB] OR "sexual"[TIAB] OR "donor selection"[Mesh] OR "selection"[TIAB])

Embase®

('blood donors'/exp OR 'blood donor':ti,ab OR 'blood donors':ti,ab OR 'blood donation'/exp OR 'blood donation':ti,ab OR 'blood donations':ti,ab OR 'blood banks'/exp OR 'blood banks':ti,ab OR 'blood bank':ti,ab OR 'blood service':ti,ab OR 'blood services':ti,ab OR 'blood centre':ti,ab OR 'blood centres':ti,ab OR 'blood centre':ti,ab OR 'blood centres':ti,ab OR 'blood transfusion'/exp OR transfusion:ti,ab)

AND

('hiv infections'/exp OR HIV:ti,ab OR 'hepatitis b virus'/exp OR 'hepatitis b':ti,ab OR HBV:ti,ab OR 'hepatitis c':ti,ab OR HCV:ti,ab OR 'treponemal infections'/exp OR syphilis:ti,ab OR 'Treponema pallidum':ti,ab OR 'communicable disease, emerging':exp OR emerging:ti,ab OR 'residual risk':ti,ab OR 'infection':ti,ab OR infection':ti,ab OR 'transfusion-transmitted':ti,ab OR 'transfusion transmissible':ti,ab OR TT':ti,ab OR 'blood safety'/exp OR 'blood safety':ti,ab OR 'transfusion safety':ti,ab)

AND

(‘models, theoretical’/exp OR ‘models, statistical’/exp OR ‘bayes theorem’/exp OR model:ti,ab OR models:ti,ab OR modelling:ti,ab OR modeling:ti,ab OR modelled:ti,ab OR modelled:ti,ab OR ‘computer simulation’/exp OR simulation:ti,ab OR predict:ti,ab OR prediction:ti,ab OR predicted:ti,ab OR estimate:ti,ab OR estimates:ti,ab OR estimated:ti,ab OR estimation:ti,ab OR scenario:ti,ab OR scenarios:ti,ab)

AND

(deferral:ti,ab OR ban:ti,ab OR lifetime:ti,ab OR ‘risk assessment’:ti,ab OR ‘men who have sex with men’:ti,ab OR MSM:ti,ab OR ‘men who have had sex with men’:ti,ab OR homosexuality, male’/exp OR gay:ti,ab OR bisexual:ti,ab OR ‘donor selection’/exp OR selection:ti,ab)

CINAHL

((MH “blood donors+”) OR (TI “blood donor” OR AB “blood donor”) OR (TI “blood donors” OR AB “blood donors”) OR (MH “blood donation+”) OR (TI “blood donation” OR AB “blood donation”) OR (TI “blood donations” OR AB “blood donations”) OR (MH “blood banks+”) OR (TI “blood banks” OR AB “blood banks”) OR (TI “blood bank” OR AB “blood bank”) OR (TI “blood service” OR AB “blood service”) OR (TI “blood services” OR AB “blood services”) OR (TI “blood center” OR AB “blood center”) OR (TI “blood centers” OR AB “blood centers”) OR (TI “blood centre” OR AB “blood centre”) OR (TI “blood centres” OR AB “blood centres”) OR (MH “blood transfusion+”) OR (TI transfusion OR AB transfusion))

AND

((MH “hiv infections+”) OR (TI HIV OR AB HIV) OR (MH “hepatitis b virus+”) OR (TI “hepatitis b” OR AB “hepatitis b”) OR (TI HBV OR AB HBV) OR (TI “hepatitis c” OR AB “hepatitis c”) OR (TI HCV OR AB HCV) OR (MH “treponemal infections+”) OR (TI syphilis OR AB syphilis) OR (TI “treponema pallidum” OR AB “treponema pallidum”) OR (MH “communicable disease, emerging+”) OR (TI emerging OR AB emerging) OR (TI “residual risk” OR AB “residual risk”) OR (TI infection OR AB infection) OR (TI infections OR AB infections) OR (TI transfusion-transmitted” OR AB transfusion-transmitted”) OR (TI “transfusion transmissible” OR AB “transfusion transmissible”) OR (TI TTI OR AB TTI) OR (MH “blood safety+”) OR (TI “blood safety” OR AB “blood safety”) OR (TI “transfusion safety” OR AB “transfusion safety”))

AND

((MH “models, theoretical+”) OR (MH “models, statistical+”) OR (MH “bayes theorem+”) OR (TI model OR AB model) OR (TI models OR AB models) OR (TI modelling OR AB modelling) OR (TI modeling OR AB modeling) OR (TI modelled OR AB modelled) OR (TI modelled OR AB modelled) OR (MH “computer simulation+”) OR (TI simulation OR AB simulation) OR (TI predict OR AB predict) OR (TI prediction OR AB prediction) OR (TI predicted OR AB predicted) OR (TI estimate OR AB estimate) OR (TI estimates OR AB estimates) OR (TI estimated OR AB estimated) OR (TI estimation OR AB estimation) OR (TI scenario OR AB scenario) OR (TI scenarios OR AB scenarios))

AND

((TI deferral OR AB deferral) OR (TI ban OR AB ban) OR (TI lifetime OR AB lifetime) OR (TI “risk assessment” OR AB “risk assessment”) OR (TI “men who have sex with men” OR AB “men who have sex with men”) OR (TI men who have sex with men OR AB men who have sex with men) OR (TI “men who have had sex with men” OR AB

"men who have had sex with men") OR (MH "homosexuality, male+") OR (TI gay OR AB gay) OR (TI bisexual OR AB bisexual) OR (MH "donor selection+") OR (TI selection OR AB selection))

Web of Science

(ALL = "blood donors" OR (TI = "blood donor" OR AB = "blood donor") OR (TI = "blood donors" OR AB = "blood donors") OR ALL = "blood donation" OR (TI = "blood donation" OR AB = "blood donation") OR (TI = "blood donations" OR AB = "blood donations") OR ALL = "blood banks" OR (TI = "blood banks" OR AB = "blood banks") OR (TI = "blood bank" OR AB = "blood bank") OR (TI = "blood service" OR AB = "blood service") OR (TI = "blood services" OR AB = "blood services") OR (TI = "blood centre" OR AB = "blood centre") OR (TI = "blood centres" OR AB = "blood centres") OR (TI = "blood centre" OR AB = "blood centre") OR (TI = "blood centres" OR AB = "blood centres") OR ALL = "blood transfusion" OR (TI = transfusion OR AB = transfusion))

AND

(ALL = "hiv infections" OR (TI = HIV OR AB = HIV) OR ALL = "hepatitis b virus" OR (TI = "hepatitis b" OR AB = "hepatitis b") OR (TI = HBV OR AB = HBV) OR (TI = "hepatitis c" OR AB = "hepatitis c") OR (TI = HCV OR AB = HCV) OR ALL = "treponemal infections" OR (TI = syphilis OR AB = syphilis) OR (TI = "*Treponema pallidum*" OR AB = "*Treponema pallidum*") OR ALL = "communicable disease, emerging" OR (TI = emerging OR AB = emerging) OR (TI = "residual risk" OR AB = "residual risk") OR (TI = infection OR AB = infection) OR (TI = infections OR AB = infections) OR (TI = transfusion-transmitted OR AB = transfusion-transmitted) OR (TI = "transfusion transmissible" OR AB = "transfusion transmissible") OR (TI = TTI OR AB = TTI) OR ALL = "blood safety" OR (TI = "blood safety" OR AB = "blood safety") OR (TI = "transfusion safety" OR AB = "transfusion safety"))

AND

(ALL = "models, theoretical" OR ALL = "models, statistical" OR ALL = "bayes theorem" OR (TI = model OR AB = model) OR (TI = models OR AB = models) OR (TI = modelling OR AB = modelling) OR (TI = modeling OR AB = modeling) OR (TI = modelled OR AB = modelled) OR (TI = modelled OR AB = modelled) OR ALL = "computer simulation" OR (TI = simulation OR AB = simulation) OR (TI = predict OR AB = predict) OR (TI = prediction OR AB = prediction) OR (TI = predicted OR AB = predicted) OR (TI = estimate OR AB = estimate) OR (TI = estimates OR AB = estimates) OR (TI = estimated OR AB = estimated) OR (TI = estimation OR AB = estimation) OR (TI = scenario OR AB = scenario) OR (TI = scenarios OR AB = scenarios))

AND

((TI = deferral OR AB = deferral) OR (TI = ban OR AB = ban) OR (TI = lifetime OR AB = lifetime) OR (TI = "risk assessment" OR AB = "risk assessment") OR (TI = "men who have sex with men" OR AB = "men who have sex with men") OR (TI = MSM OR AB = MSM) OR (TI = "men who have had sex with men" OR AB = "men who have had sex with men") OR ALL = "Homosexuality, Male" OR (TI = gay OR AB = gay) OR (TI = bisexual OR AB = bisexual) OR (TI = sexual OR AB = sexual) OR ALL = "donor selection" OR (TI = selection OR AB = selection))

Table 1. Characteristics of the included studies on the effect of donor exclusion criteria on blood safety and volume of donations

First author	Country	Modelling method (model type) ^a	Deferral policy on men who have sex with men ^b		Outcomes modelled	
			Baseline	Modelled	Blood safety	Volume
Germain et al., 2003 ¹⁸	USA and Canada	Monte Carlo simulation (stochastic)	Lifetime	1 year	HIV residual risk per million donations	Additional number of new donors
Soldan et al., 2003 ¹⁹	England	Mathematical model (deterministic)	Lifetime	1 year	Additional number of HIV-positive blood units released	Additional number of new donors
Anderson et al., 2009 ²⁰	USA	Monte Carlo simulation (stochastic)	Lifetime	5 years; 1 year	Additional number of HIV-positive or hepatitis B virus-positive blood units released	Additional number of new donors
Davison et al., 2011 ²¹	United Kingdom	Mathematical equation model (deterministic)	Lifetime	5 years	HIV residual risk per million donations	Not reported
Pillonel et al., 2012 ²²	France	Mathematical equation model (deterministic)	Lifetime	IRA	HIV residual risk per million donations	Additional donor-years
Davison et al., 2013 ²³	United Kingdom	Mathematical equation model (deterministic)	Lifetime	1 year	HIV residual risk per million donations	Additional number of new donors
Germain et al., 2014 ²⁴	USA and Canada	Monte Carlo simulation (stochastic)	Lifetime	5 years	Number of additional HIV-positive blood units released	Additional number of new donors
Ginsberg et al., 2016 ²⁵	Israel	Mathematical equation model (deterministic)	Lifetime	5 years; 1 year; IRA	HIV cases transmitted in the next decade	Additional number of new donations
Yang et al., 2016 ²⁶	USA	Monte Carlo simulation (stochastic)	Lifetime	No risk deferral	Additional number of HIV-positive blood units released	Additional number of new donations
Davison et al., 2019 ²⁷	United Kingdom and Canada	Monte Carlo simulation (stochastic)	Lifetime	1 year	HIV residual risk per million donations	Not reported
O'Brien et al., 2020 ²⁸	Canada	Monte Carlo simulation (stochastic)	5 years	1 year	HIV residual risk per million donations	Additional number of new donors
Pillonel et al., 2020 ²⁹	France	Monte Carlo simulation (stochastic)	1 year	3 months	HIV residual risk per million donations	Additional number of new donors
				4 months; IRA	HIV residual risk per million donations	

Publication: Bulletin of the World Health Organization; Type: Systematic reviews
 Article ID: BLT.25.294318

Aubé et al., 2022 ³⁰	Canada	Bayesian network with Monte Carlo simulation (stochastic)	3 months for plasma donors	IRA for plasma donations	Probability of obtaining a plasma pool with an HIV viral load	Not reported
Caffrey et al., 2022 ³¹	Canada	Monte Carlo simulation (stochastic)	3 months	IRA	HIV residual risk per million donations	Additional number of new donors

HIV: human immunodeficiency virus

^a Stochastic parameters are described by probability distributions and deterministic parameters are fixed.

^b Lifetime: permanent deferral of men who have sex with men; 5 years, 1 year and 3 months: deferral of men who have sex with men for 5 years, 1 year and 3 months, respectively, after last sexual contact between men; IRA: individual risk assessment for all blood donors, with no specific deferral for men who have sex with men; no risk deferral: absence of any risk-based deferrals for all donors.

Table 2. Risk of bias assessment of individual modelling studies on the effect of donor exclusion criteria on blood safety and volume of donations

Model, by risk of bias	Score by category						
	Definitions (0–8)	Model methods (0–4)	Model inputs (0– 6)	Fitting and validation (0–4)	Results (0–4)	Conflict of interest (0– 2)	Total (0–28)
Low risk (total score of ≥ 19)							
Davison, 2019 ²⁷	7	4	5	2	4	1	23
Anderson, 2009 ²⁰	7	4	6	0	4	2	23
Caffrey, 2022 ³¹	7	4	3	2	3	2	21
Pillonel, 2020 ²⁹	7	4	5	0	4	1	21
Davison, 2011 ²¹	7	3	4	0	3	2	19
O'Brien, 2020 ²⁸	6	4	4	0	4	1	19
Medium risk (total score of 15–18)							
Davison, 2013 ²³	7	3	4	0	2	2	18
Germain, 2014 ²⁴	6	3	5	0	3	1	18
Pillonel, 2012 ²²	7	1	3	0	3	2	16
Yang, 2016 ²⁶	5	3	3	0	3	2	16
Germain, 2003 ¹⁸	7	4	2	0	2	0	15
High risk (total score of ≤ 14)							
Aubé, 2022 ³⁰	7	0	2	0	3	2	14
Soldan, 2003 ¹⁹	7	1	3	0	2	0	13
Ginsberg, 2016 ²⁵	5	3	0	0	3	1	12

Note: The grading scale has 14 questions on definitions, model methods, model inputs, fitting and validation, results, and conflicts of interest. Each question was scored 0, 1 or 2 points, resulting in an overall score ranging from 0 to 28.

Table 3. Modelled outcomes of changes in policies on blood donation from men who have sex with men

Model	Modelled effect estimates		
	HIV residual risk [certainty of evidence]	Additional number of HIV or HBV-positive blood units detected annually [certainty of evidence]	Additional number of donors or donations [certainty of evidence]
From permanent ban on donation to a 5-year deferral	0.004% or 0.001 additional HIV-positive units per million donations [moderate] ²⁰	0.03% or 1 additional HIV-positive unit every 6 476 years (95% CI: 2005–16 545 years) [moderate] ^{20,21} 0.004% additional HBV-positive units [moderate] ²⁴ 0.1% (HIV-positive units) [low] ^{19,20} 0.019% (HBV-positive units) [moderate] ²⁴	Annual increase in new donors of 0.04–0.17%, equating to 4530 additional donors [low] ^{24,29,30}
From permanent ban to a 1-year deferral	0.004–65% or 0.001–0.12 additional HIV-positive units per million donations [low] ^{18,23,27}	49 additional HIV positive blood units annually in the USA [very low] ²⁶	Annual increase in new donors of 0.88–1.3% [moderate] ^{18–20,23,25,27}
From permanent ban to no deferral	Effect ranging between increases of 26% to 370% (worst-case scenario), corresponding to between 0.01 and 1.1 (worst case) additional HIV positive units per million donations [very low] ^{19,21,22}	49 additional HIV positive blood units annually in the USA [very low] ²⁶	Annual increase in donors of 0.75–2.1% [very low] ^{19,22,25}
From a 5-year to a 1-year deferral	0–30% increase or 0.000–0.015 additional HIV-positive units per million donations [moderate] ²⁷	Not modelled	Not modelled
From a 1-year to a 3–4 month deferral	1–11% increase or 0.000–0.003 additional HIV-positive units per million donations [moderate] ^{28,29}	Not modelled	Annual increase in donors 0.24%, or 446 additional yearly donors [moderate] ^{28,29}
From a 1-year deferral to no deferral	43% increase or 0.07 additional HIV-positive units per million donations [moderate]	Not modelled	Not modelled
From a 3-month deferral to no deferral	300% increase in HIV residual risk per million donations, or 0.04 additional HIV-positive units per million donations [moderate] ²⁵	Not modelled	Annual increase in donors of 1.67% [moderate] ³¹

CI: confidence interval; HBV: hepatitis B virus; HIV: human immunodeficiency virus.

Note: further results are presented in Fig. 2.

Fig. 1. Flowchart of the selection of modelling studies on the effect of donor exclusion criteria on blood safety and volume of donations





Fig. 2. HIV residual risk in models of reduced deferral lengths on blood donations from men who have sex with men



HIV: human immunodeficiency virus.

Note: Error bars indicate the distribution of estimates from the Monte Carlo simulations.